英文药名：Starasid Cap（Cytarabine Ocfosphate Hydrate） 中文药名：阿糖胞苷磷酸盐水合物 生产厂家：日本化药 スタラシドカプセル５０／スタラシドカプセル１００ 类别名称 抗肿瘤药 欧文商標名 Starasid Cap.50 Starasid Cap.100 一般名： シタラビン オクホスファート水和物(Cytarabine Ocfosphate Hydrate) 化学名： 4-amino-1-β-D-arabinofuranosyl-2(1H )-pyrimidinone 5'-(sodium octadecyl phosphate)monohydrate 分子式： C27H49N3NaO8P・H2O 分子量： 615.67 構造式： 性状： 阿糖胞苷Okuhosufato水合物是一种白色结晶或结晶性粉末。 适应病症 ●成人急性非淋巴细胞白血病（该优先级给予该疗法的患者强大化疗成为主体。） ●骨髓增生异常综合征（骨髓增生异常综合征） 用法用量 ●成人急性非淋巴细胞白血病 每天100〜300毫克2〜3周连续口服给药，随后停药两至三个星期。这是重复的。应当指出的是，剂量根据病情，症状等进行调整。这种药物和饭后给药的定时，考虑分成每天一至三次。 ●骨髓增生异常综合征（骨髓增生异常综合征） 每天100〜200毫克2〜3周连续口服给药，随后停药两至三个星期。这是重复的。应当指出的是，剂量根据病情，症状等进行调整。这种药物和饭后给药的定时，考虑分成每天一至三次。 药效药理 1. 抗肿瘤作用 本剤口服给药时，显示出在各种小鼠肿瘤生存益处，包括L1210白血病。这种效果是依赖于总剂量上不依赖于施用的时间安排。 也表现出阿霉素，道诺霉素，丝裂霉素C，与在小鼠P388白血病顺铂或长春新碱两种药物同时结合一个显著协同效应。 2. 作用机序 本剤在体内，ARA-CTP在肿瘤细胞中，通过抑制DNA聚合酶的抗肿瘤效果下被代谢成阿糖胞苷活性代谢物的后面，表示阿糖胞苷，的前药。 包装规格 胶囊 50毫克：40粒、100粒 100毫克：40粒 制造厂商 日本化药有限公司 完整处方资料附件：http://www.info.pmda.go.jp/go/pack/4224001M1020_1_11/ Starasid Cap（Cytarabine ocfosfate） Brand name : Starasid Cap. 50 　Active ingredient: Cytarabine ocfosfate 　Dosage form: magenta/white capsule (size 3 capsule) 　Print on wrapping: スタラシドカプセル50,スタラシド,50mg,NK7025 ,Staraside Cap Effects of this medicine This medicine inhibits DNA (deoxyribonucleic acid) synthesis of cancer cells to suppress their growth. It is used to treat adult acute non-lymphatic leukemia or myelodysplastic syndrome. Before using this medicine, be sure to tell your doctor and pharmacist •If you have previously experienced any allergic reactions (itch, rash, etc.) to any medicines. If you are a patient with marrow depression, infection, liver disorder. •If you are pregnant or breastfeeding. •If you are taking any other medicinal products. (Some medicines may interact to enhance or diminish medicinal effects. Beware of over-the-counter medicines and dietary supplements as well as other prescription medicines.) Dosing schedule (How to take this medicine) •Your dosing schedule prescribed by your doctor is <<to be written by a healthcare professional>> •For adult acute non-lymphatic leukemia: In general, for adults, take 2-6 capsules (100-300mg of the active ingredient anhydride) in 1-3 divided doses a day after meal. For myelodysplastic syndrome: In general, for adults, take 2-4 capsules (100-200mg of the active ingredient anhydride) in 1-3 divided doses a day after meal, for 2 to 3 weeks every day, then discontinue the medication for 2-3 weeks and repeat this schedule. The dosage may be adjusted according to your disease or symptoms.Strictly follow the instructions. •If you miss a dose, take the missed dose as soon as possible. If it is almost time for the next dose, skip the missed dose and follow your regular dosing schedule. You should never take two doses at one time. •If you accidentally take more than your prescribed dose, consult with your doctor or pharmacist. •Do not stop taking this medicine unless your doctor instructs you to do so. Precautions while taking this medicine • Possible adverse reactions to this medicine The most commonly reported adverse reactions include loss of appetite, nausea/vomiting, fever, malaise and rash. If any of these symptoms occur, consult with your doctor or pharmacist. The symptoms described below are rarely seen as initial symptoms of the adverse reactions indicated in brackets. If any of these symptoms occur, stop taking this medicine and see your doctor immediately. •anemia, fever, bleeding tendency (nasal bleeding, bleeding gums, bleeding under the skin), malaise [marrow depression include pancytopenia] •fever, dry cough, breathing difficulty [interstitial pneumonia] The above symptoms do not describe all the adverse reactions to this medicine. Consult with your doctor or pharmacist if you notice any symptoms of concern other than those listed above. Storage conditions and other information •Keep out of the reach of children. Store away from direct sunlight, heat and moisture. •Discard the remainder. Do not store them. Ask your pharmacist how to discard. NIPPON KAYAKUInternal Published: 3/2008 The information on this sheet is based on approvals granted by the Japanese regulatory authority. Approval details may vary by country. Medicines have adverse reactions (risks) as well as efficacies (benefits). It is important to minimize adverse reactions and maximize efficacy. To obtain a better therapeutic response, patients should understand their medication and cooperate with the treatment. 阿糖胞苷 (Cytarabine)　国外自50年代于隐南瓜海绵中发现了胸腺嘧啶核苷，简称海绵胸苷，此后又分离出海绵尿苷及海绵核苷，它们均属于阿拉伯糖苷类，以游离状态存在于海绵组织中。我国于南海岁氏豆荚软珊瑚 Lobophytum chevalieri 及佳丽鹿角珊瑚 Acropora pulchra 中均提得了胸腺嘧啶、胸腺嘧啶脱氧核苷等。这些化合物的发现为人们合成核苷类药物提供了天然模式。在此基础上，后来合成了D-阿拉伯糖胞嘧啶，即现在的阿糖胞苷 (Arabinoside Cytosine, Ara-C)[66]，能通过抑制DNA聚合酶而干扰DNA的合成。临床主要治疗急性白血病及消化道癌，对单纯疱疹性结膜炎亦有效。目前应用最广的抗癌药氟尿嘧啶，也是据此设想合成的